newsfilter
← Latest News
Business Wire·

Axcella Therapeutics Announces FDA Fast Track Designation for AXA1125 in NASH

Designation provides the potential for an expedited drug development path EMMPACT℠ Phase 2b clinical trial enrolling well, with interim data expected in mid-2022 Axcella Therapeutics (NASDAQ:AXLA), a clinical-stage biotechnology company pio